Abbott Hits Hospira With Patent Suit Over Zemplar

Law360, New York (July 22, 2011, 4:30 PM EDT) -- Abbott Laboratories slapped Hospira Inc. with a lawsuit Thursday in Delaware federal court, claiming that Hospira infringed two patents by trying to tap into the market for paricalcitol, which Abbott markets as the kidney disease treatment Zemplar.

The plaintiff claims Lake Forest, Ill.-based Hospira infringed the patents-in-suit when it filed New Drug Application No. 201-657 pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, seeking a green light from the U.S. Food and Drug Administration for three formulations of injectable paricalcitol drug products...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.